Research location
Golden Valley
Minnesota, United States
Advertisement
Research activity in Golden Valley
Minnesota, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 99 trials and 103 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Golden Valley
99 linked trials · page 1 of 2A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)NCT07589595 · 2026-05-20 · 1 site observation
RECRUITING
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderNCT06793397 · 2025-12-10 · 1 site observation
RECRUITING
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's DiseaseNCT06680830 · 2025-01-17 · 1 site observation
RECRUITING
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)NCT06433752 · 2024-07-22 · 1 site observation
RECRUITING
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabNCT05877963 · 2023-06-13 · 1 site observation
RECRUITING
Parkinson's Foundation PD GENEration Genetic RegistryNCT04994015 · 2020-12-20 · 1 site observation
RECRUITING
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple SclerosisNCT05949580 · 2024-10-21 · 1 site observation
SUSPENDED
Continuous Wearable Monitor for the Detection and Release of Freezing of Gait.NCT06385392 · 2024-09-11 · 1 site observation
COMPLETED
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.NCT06372145 · 2024-04-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple SclerosisNCT06141486 · 2023-12-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Early Parkinson's Disease Monotherapy With CVN424NCT06006247 · 2023-09-11 · 1 site observation
COMPLETED
A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's DiseaseNCT05424276 · 2023-05-15 · 1 site observation
COMPLETED
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's DiseaseNCT05766813 · 2023-03-13 · 1 site observation
COMPLETED
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple SclerosisNCT05269004 · 2022-05-03 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple SclerosisNCT04544449 · 2020-10-26 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of TAK-071 in People With Parkinson DiseaseNCT04334317 · 2020-10-21 · 1 site observation
COMPLETED
A Clinical Study of NLY01 in Patient's With Early Parkinson's DiseaseNCT04154072 · 2020-02-27 · 1 site observation
COMPLETED
NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)NCT04148391 · 2019-11-14 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)NCT03933202 · 2019-07-22 · 1 site observation
COMPLETED
PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706NCT03655236 · 2019-02-18 · 1 site observation
TERMINATED
A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab AdministrationNCT03689972 · 2018-11-27 · 1 site observation
COMPLETED
A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor FluctuationsNCT03670953 · 2018-11-06 · 1 site observation
COMPLETED
A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking ImpairmentNCT03567057 · 2018-07-18 · 1 site observation
COMPLETED
Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking ImpairmentNCT03436199 · 2018-03-29 · 1 site observation
COMPLETED
Compass Course: Efficacy StudyNCT03442686 · 2018-03-02 · 1 site observation
COMPLETED
A Phase 3 Study With P2B001 in Subjects With Early Parkinson'sNCT03329508 · 2018-01-19 · 1 site observation
COMPLETED
A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg FingolimodNCT03257358 · 2017-09-19 · 1 site observation
COMPLETED
Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.NCT03051607 · 2017-04-10 · 2 site observations
TERMINATED
Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)NCT03085810 · 2017-03-24 · 1 site observation
TERMINATED
A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2NCT03093324 · 2017-03-15 · 1 site observation
COMPLETED
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)NCT02936037 · 2016-12-01 · 1 site observation
TERMINATED
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple SclerosisNCT02792218 · 2016-09-20 · 1 site observation
COMPLETED
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.NCT02792231 · 2016-08-26 · 1 site observation
COMPLETED
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)NCT02776072 · 2016-05-01 · 1 site observation
COMPLETED
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)NCT02637856 · 2016-02-11 · 1 site observation
COMPLETED
Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®NCT02823951 · 2016-02-01 · 1 site observation
COMPLETED
A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1NCT02634307 · 2015-12-10 · 1 site observation
COMPLETED
Mirabegron in Parkinson Disease and Impaired CognitionNCT02536976 · 2015-12-01 · 1 site observation
COMPLETED
A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple SclerosisNCT02545868 · 2015-10-27 · 1 site observation
COMPLETED
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple SclerosisNCT02576717 · 2015-10-16 · 1 site observation
COMPLETED
Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's DiseaseNCT02542696 · 2015-08-31 · 1 site observation
COMPLETED
Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®NCT02499900 · 2015-08-10 · 2 site observations
COMPLETED
Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF EpisodesNCT02242487 · 2015-03-01 · 1 site observation
COMPLETED
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to PlaceboNCT02284568 · 2015-01-12 · 2 site observations
COMPLETED
SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)NCT02258152 · 2014-12-22 · 1 site observation
COMPLETED
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis TrialNCT02089217 · 2014-12-09 · 1 site observation
COMPLETED
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)NCT02294058 · 2014-12-03 · 1 site observation
COMPLETED
Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple SclerosisNCT02330965 · 2014-12-01 · 1 site observation
COMPLETED
Plegridy Observational ProgramNCT02230969 · 2014-11-12 · 1 site observation
COMPLETED
Efficacy of Isradipine in Early Parkinson DiseaseNCT02168842 · 2014-11-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.